How to Choose In Vitro Systems to Predict In Vivo Drug Clearance: A System Pharmacology Perspective by Wang, Lei et al.
Research Article
How to Choose In Vitro Systems to Predict In Vivo Drug
Clearance: A System Pharmacology Perspective
Lei Wang,1,2 ChienWei Chiang,3,4 Hong Liang,1,2 Hengyi Wu,3,4 Weixing Feng,1,5
Sara K. Quinney,3,6 Jin Li,1,2 and Lang Li3,7
1Bioinformatics Research Center, College of Automation, Harbin Engineering University, Harbin, Heilongjiang 150001, China
2Biomedical Engineering Institute, College of Automation, Harbin Engineering University, Harbin, Heilongjiang 150001, China
3Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN 46202, USA
4School of Informatics and Computing, Indiana University, Indianapolis, IN 46202, USA
5Pattern Recognition and Intelligent System Institute, College of Automation, Harbin Engineering University,
Harbin, Heilongjiang 150001, China
6Department of Obstetrics and Gynecology, School of Medicine, Indiana University, Indianapolis, IN 46202, USA
7Department of Medical and Molecular Genomics, School of Medicine, Indiana University, Indianapolis, IN 46202, USA
Correspondence should be addressed to Jin Li; lijin@hrbeu.edu.cn
Received 13 November 2014; Revised 23 January 2015; Accepted 4 February 2015
Academic Editor: Stelvio M. Bandiera
Copyright © 2015 Lei Wang et al.This is an open access article distributed under the Creative CommonsAttribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The use of in vitro metabolism data to predict human clearance has become more significant in the current prediction of large
scale drug clearance for all the drugs. The relevant information (in vitro metabolism data and in vivo human clearance values) of
thirty-five drugs that satisfied the entry criteria of probe drugs was collated from the literature. Then the performance of different
in vitro systems including Escherichia coli system, yeast system, lymphoblastoid system and baculovirus system is compared after in
vitro-in vivo extrapolation. Baculovirus system, which can provide most of the data, has almost equal accuracy as the other systems
in predicting clearance. And in most cases, baculovirus system has the smaller CV in scaling factors. Therefore, the baculovirus
system can be recognized as the suitable system for the large scale drug clearance prediction.
1. Introduction
In vivo drug clearance is a very significant pharmacokinetic
parameter, which largely determines the drug exposure in
human body [1, 2]. Predicting the clinical in vivo drug
clearance from the preclinical in vitro experiments is essential
during the drug development. Specifically, hepatic clearance
(CLH) is the most important clearance parameter as the
majority of the drugs are metabolized in human liver [3].
The most common in vitro drug clearance methods
include the use of human liver microsomes (HLMs) or
hepatocytes [4], which are well documented in the literature
[5–8].The advantage of HLMs and human hepatocytes is that
they are physiologically closer to human liver [4, 9, 10]. Their
disadvantages include enormous problems between sample
variations with unknown causes and relative high expense
[11, 12]. In particular, the large variation of in vitro experi-
ments in HLMs or hepatocytes causes the doubts in repro-
ducibility. On the other hand, the commercial availability
of recombinant human enzyme expression systems makes
the prediction of human drug clearance cheaper and more
reproducible [13, 14]. The advantages and limitations of each
in vitro approach are well documented [15–21].
In order to predict in vivo clearance from in vitro
experiments, system pharmacology model, such as the phys-
iologically based pharmacokinetic (PBPK) model have been
developed rapidly [22–25]. Yap et al. [26] present statistical
learning models based on mixed physicochemical and topo-
logical descriptors. Demir-Kavuk et al. [27] develop a single
application called DemQSAR. Simcyp [28] and Gastroplus
[29] are developed originally in collaboration with major
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pharmaceutical companies to simulate and predict drug
clearance and drug interaction in virtual patient populations.
Despite the previously described advances in both tech-
nology and system pharmacology modeling, in vitro drug
clearance prediction still faces some new challenges [25, 30].
There are a number of in vitro recombinant enzyme systems
available, but it is not clear whether they all perform similarly
or differently. The performance of different recombinant
systems can also be enzyme dependent, but little was known
about it [30]. Finally and most importantly, unlike tradi-
tional physiologically based pharmacokinetics modeling that
investigates one or a few drugs a time, current translational
bioinformatics desires a systemmodel that can conduct large
scale drug clearance for all the drugs [31]. This is a new
challenge that poses not only the accuracy of the in vitro-
in vivo clearance prediction, but also the completeness and
variations of the annotated in vitro recombinant experiment
data on drug metabolisms. As the in vitro-in vivo clearance
prediction has been well documented in the literature, this
paper will address the completeness and variations of various
in vitro recombinant experiments.
2. Methods
2.1. In Vitro Experimental Data Collection. All the in vitro
data of selected drugs were collated from the published
literature after identifying sources using PubMed.The criteria
for drug selection were that they were recognized as probes
for specific cytochrome P450s (CYP) or metabolized mostly
by a single CYP enzyme [49, 50]. Probe drugs refer to drugs
whose plasma AUC values had been shown to increase 5-fold
or higher when coadministered with a known CYP inhibitor
or AUC ratio in poor metabolizers versus 1280 extensive
metabolizers is greater than 5-fold [50]. These literature data
including 𝑉max (pmol min
−1 pmol−1CYP), 𝐾
𝑚
(pM) were
obtained from various systems for heterologous expression of
recombinant P450 enzymes containing bacterial expression
in Escherichia coli, expression in yeast cells, lymphoblastoid
expression systems, and baculovirus-driven expression in
insect cells. Fraction unbound in plasma (fu) of drugs was
also collected. If intervals of the fraction of drug unbound
in plasma parameters were collected, the mean of an interval
was the acceptable value.
2.2. In Vivo Data Collection. Human clearance values were
taken from published original work and in part reported by
Obach et al. [32]. Both intravenous data and oral data were
accepted. In the case of oral clearance, the clearancewas taken
as a product of oral clearance and absolute bioavailability of
the drug, in order to calculate drugs’ intravenous clearance.
The bioavailability was got through Drug Bank [39] and
published original literature with a single point or the mean
of an interval. At the end, only the intravenous clearance was
used to assess in vitro-in vivo clearance prediction.
2.3. In Vitro-In Vivo Extrapolation. Prediction of drug hep-
atic clearance using in vitro recombinant P450 enzyme
kinetic parameters was performed in three main steps.
Initially, intrinsic clearance per unit enzyme (CLint,rec) was
calculated by the following:
CLint,rec =
Vmax
𝑘
𝑚
. (1)
The median CLint,rec value of the same recombinant P450
enzymes expression systems for each drug was taken, respec-
tively.
After that, CLint,rec was converted to a whole organ intrin-
sic metabolic clearance (CLint) using enzyme abundance,
MPPGL, and the liver weight as shown in the following:
CLint = (
𝑚
∑
𝑗=1
CLint,rec ⋅ enzyme abundance)
⋅MPPGL ⋅ liver weight,
(2)
where there were𝑚 CYPs with corresponding CLint,rec values
for different pathways in each recombinant system; enzyme
abundance refers to the amount (pmol P450) per milligram
of microsomal protein; MPPGL means the amount (mg) of
microsomal protein per gram of liver; and the liver weight
means the weight (g) of human liver. Enzyme abundance,
MPPGL, liver weight, and liver blood flow were generated
by Simcyp with 1000 Sim-healthy volunteers (age: 20–50),
female/male ratio 1, and 100% of extensive metabolizer for all
major CYP enzymes [51].
At last, the value of CLint was combined with binding
parameters (𝑓ub) and liver blood flow (𝑄H) to extrapolate to
whole organ clearance bywell-stirredmodel by the following:
CLH =
CLint × 𝑄H × 𝑓ub
CLint + 𝑄H × 𝑓ub
, (3)
where 𝑓ub is the fraction of drug unbound in blood. So, it
could be calculated by 𝑓u/𝐵/𝑃 ratios. While 𝐵/𝑃 ratios were
not all available from the literature, a default value of 0.55
was used. Meanwhile, nonspecific microsomal binding was
ignored.
2.4. Scaling Factor. The scaling factor of each probe drug was
assessed from the difference between predicted and observed
in vivo values as described in the following:
Scaling Factor = log
2
(
CLH,in vivo
CLH,predicted
) , (4)
where CLH,in vivo is the observed in vivo clearance and
CLH,predicted is the predicted value.Then, the scaling factor for
different enzymes was determined by averaging scaling factor
of probe drugs with the same recombinant P450 enzymes
expression systems. This value also could assess the accuracy
of clearance predicting. For one drug, if the scaling factor in
one system was identical to the others, they had the same
accuracy in predicting.
2.5. Statistical Analysis. All data were presented as mean ±
S.E., unless stated otherwise. To measure the variability of
prediction, the coefficient of variation (CV) was utilized.This
CV measures the technical variations of in vitro metabolism
experiments published from different labs.
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Table 1: Drug set.
Drug Expression systems In vivo clearance(L/h) References
Caffeine Baculovirus 5.88 Obach et al. (2008) [32]
Melatonin Baculovirus 57.96 Mallo et al. (1990) [33]
Tacrine Yeast 235.2 Obach et al. (2008) [32]
Theophylline (1,3-DMX) E. coli and lymphoblastoid 3.612 Obach et al. (2008) [32]
Bupropion Baculovirus 5.415 Lei et al. (2010) [34], Hill et al. (2007) [35]
Efavirenz Baculovirus 5.483 Gengiah et al. (2012) [36], Chiappetta et al.(2010) [37]
Repaglinide Baculovirus 32.76 Obach et al. (2008) [32]
Paclitaxel Baculovirus 26.88 Obach et al. (2008) [32]
(R)-Warfarin Baculovirus, E. coli, andlymphoblastoid 0.231 Obach et al. (2008) [32]
Phenytoin Baculovirus and lymphoblastoid 3.906 Hayes et al. (1975) [38]
Celecoxib Lymphoblastoid and yeast 21.05 Drug Bank [39], Paulson et al. (2001) [40]
Clobazam Baculovirus 2.49 Drug Bank [39]
(R)-Lansoprazole
(dexlansoprazole) Baculovirus 18.48 Obach et al. (2008) [32]
(R)-Omeprazole Baculovirus and lymphoblastoid 35.28 Obach et al. (2008) [32]
Atomoxetine Baculovirus 15.435 Drug Bank [39]
Dextromethorphan Baculovirus, E. coli, yeast, andlymphoblastoid 40.59
Moghadamnia et al. (2003) [41], Kukanich
and Papich (2004) [42]
Metoprolol Lymphoblastoid 54.6 Obach et al. (2008) [32]
Perphenazine Baculovirus 113.4 Obach et al. (2008) [32]
Tolterodine Baculovirus 10.5 Brynne et al. (1997) [43]
Venlafaxine Lymphoblastoid and yeast 40.95 Drug Bank [39]
Alfentanil Baculovirus 16.38 Obach et al. (2008) [32]
Astemizole Yeast 82.6 Lefebvre et al. (1997) [44]
Cisapride Baculovirus 14.20 Lowry et al. (2003) [45]
Cyclosporine Baculovirus 31.5 Obach et al. (2008) [32]
Felodipine Baculovirus and lymphoblastoid 46.2 Obach et al. (2008) [32]
Indinavir Baculovirus 75.6 Obach et al. (2008) [32]
Maraviroc Baculovirus 44 Abel et al (2008) [46]
Midazolam Baculovirus, E. coli, andlymphoblastoid 22.26 Obach et al. (2008) [32]
Pimozide Baculovirus 0.042 Desta et al. (1999) [47]
Quinidine Lymphoblastoid 16.8 Obach et al. (2008) [32]
Sildenafil Baculovirus 38.22 Obach et al. (2008) [32]
Sirolimus Baculovirus 2.73 Brattstram et al. (2000) [48]
Tacrolimus Baculovirus 4.63 Obach et al. (2008) [32]
Triazolam Baculovirus and lymphoblastoid 12.6 Obach et al. (2008) [32]
Vardenafil Baculovirus 54.6 Obach et al. (2008) [32]
3. Results
3.1. LiteratureDataCollection. Thirty-five drugswere consid-
ered as probe drugs for various enzymes, CYP1A2, CYP2B6,
CYP2C9, CYP2C19, CYP2D6, and CYP3A, from different
expression systems as they had relatively adequate kinetic
data, as shown in Table 1 [49, 50].
3.2. Comparison of Clearance Predictions for Different Enzyme
Probe Drugs from the Same Expression System. Since most
drugs had baculovirus system data, they were used to predict
probe drugs’ clearance. The predicted clearance was within
3-fold of the observed in vivo value for 6 of the 15 (40%)
drugs for CYP3A probe drugs. While for CYP 2D6, none of
the predicted values was within 3-fold the observed in vivo
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Table 2: Predicted value and observed in vivo value of probe drugs.
Drug Expression systems The predicted value (L/h) The observed in vivo value (L/h) Scaling factor
Caffeine Baculovirus 1.21 5.88 2.28
(R)-Lansoprazole (dexlansoprazole) Baculovirus 81.74 18.48 −2.12
(R)-Omeprazole Baculovirus 31.81 35.28 0.15
(R)-Omeprazole Lymphoblastoid 15.56 35.28 1.18
(R)-Warfarin Baculovirus 0.66 0.231 −1.51
(R)-Warfarin E.coli 0.0041 0.231 5.82
(R)-Warfarin Lymphoblastoid 0.018 0.1512 3.07
7-Epi-10-deacetyl-paclitaxel Baculovirus 1.77 26.88 3.93
Alfentanil Baculovirus 56.32 16.38 −1.79
Astemizole Yeast 40.24 82.6 1.04
Atomoxetine Baculovirus 1.65 20.99875 3.67
Bupropion Baculovirus 7.27 5.415 −0.43
Celecoxib Lymphoblastoid 41.26 21.05 −0.97
Celecoxib Yeast 5.66 21.05 1.90
Cisapride Baculovirus 20.76 14.1975 −0.56
Clobazam Baculovirus 23.02 2.49 −3.18
Cyclosporine Baculovirus 29.07 31.5 0.11
Dextromethorphan Baculovirus 11.53 15.435 0.42
Dextromethorphan E.coli 0.26 15.435 5.89
Dextromethorphan Lymphoblastoid 11.87 15.435 0.38
Dextromethorphan Yeast 21.66195 15.435 −0.49
Efavirenz Baculovirus 0.19 5.483 4.85
Felodipine Lymphoblastoid 0.83 46.2 5.80
Indinavir Baculovirus 89.11 75.6 −0.23
Maraviroc Baculovirus 33.78 44 0.38
Melatonin Baculovirus 35.52 57.96 0.70
Metoprolol Lymphoblastoid 44.05 54.6 0.31
Midazolam Baculovirus 54.9 22.26 −1.29
Midazolam E.coli 44.97 22.26 −1.03
Midazolam Lymphoblastoid 46.51 22.26 −1.06
Perphenazine Baculovirus 34.35 113.4 1.72
Phenytoin Baculovirus 0.37 3.906 3.40
Phenytoin Lymphoblastoid 1.07 3.906 1.87
Pimozide Baculovirus 6.87 0.042471 −6.64
Quinidine Lymphoblastoid 76.93 16.8 −2.18
Repaglinide Baculovirus 27.29 32.76 0.26
Sildenafil Baculovirus 5.17 38.22 2.89
Sirolimus Baculovirus 19.47 2.73 −2.84
Tacrine Yeast 16.96 235.2 3.79
Tacrolimus Baculovirus 89.11 4.634 −4.32
Theophylline (1,3-DMX) E. coli 6.6 3.612 −0.86
Theophylline (1,3-DMX) Lymphoblastoid 8.04 3.612 −1.15
Tolterodine baculovirus 2.22 10.5 2.24
Triazolam Baculovirus 46.65 12.6 −1.89
Triazolam Lymphoblastoid 4.65 12.6 1.44
Vardenafil Baculovirus 27.75 54.6 0.98
Venlafaxine Lymphoblastoid 13.91 40.95 1.56
Venlafaxine Yeast 2.76 40.95 3.89
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Table 3: Scaling factor with different enzymes and expression systems.
Enzymes Expression systems Scaling factor (mean ± SD) CV
1A2 Baculovirus 1.493 ± 1.112 74.48%
1A2 E. coli −0.869 —
1A2 Lymphoblastoid −1.154 —
1A2 Yeast 3.794 —
2B6 Baculovirus 2.232 ± 3.756 168.28%
2C8 Baculovirus 2.093 ± 2.588 123.65%
2C9 Baculovirus 0.947 ± 3.490 368.53%
2C9 E. coli 5.828 —
2C9 Lymphoblastoid 1.530 ± 2.351 153.66%
2C9 Yeast 1.894 —
2C19 Baculovirus −1.735 ± 1.716 98.90%
2C19 Lymphoblastoid 1.181 —
2D6 Baculovirus 2.394 ± 0.601 25.10%
2D6 Lymphoblastoid 1.213 ± 0.790 65.13%
2D6 E. coli 7.290 —
2D6 Yeast 2.399 ± 2.111 87.95%
3A Baculovirus −1.320 ± 2.653 200.98%
3A E. coli −1.014 —
3A Lymphoblastoid 0.993 ± 3.541 356.60%
3A Yeast 1.038 —
value. Only one drug was within 3-fold the observed value
for CYP1A2, 2B6, 2C8, 2C9, and 2C19, which accounted for
50%, 50%, 50%, 50%, and 33% of the total. These results were
illustrated in Figure 1 and Table 2.
3.3. Comparisons of Clearance Predictions in the Differ-
ent Expression Systems. Dextromethorphan and midazo-
lam were selected to compare different expression systems,
because these two drugs were investigated and published
under all these systems. For dextromethorphan, the predicted
values from yeast system were only within 3-fold the in vivo
value. And baculovirus system and lymphoblastoid system
had almost the same prediction accuracy (Figure 2, Table 2).
For midazolam, all of the predicted clearance values were
within 3-fold the in vivo clearance values. The most accurate
predicted value was from E. coli system. And the three
expression systems had almost the same prediction accuracy
(Figure 2, Table 2).
3.4. Comparison of Data Availability fromDifferent Expression
Systems. All the in vitro recombinant enzyme expression
system data were collated from the published literature. The
total number of data points was 293. Figure 3 showed the
proportion of data from different expression systems. In
general, baculovirus and lymphoblastoid system were more
abundant than the others. Baculovirus system has the largest
proportion, 67%. Lymphoblastoid systemwas the second one,
20%.Only 8%and 5%of the data came fromE. coli systemand
yeast system.
If we mapped all the data to different drugs, the majority
of the drugs (28/35) were tested in the baculovirus expression
system; part (12/35) of the selected drugs were test in the
lymphoblastoid expression systems and only 4/35 were from
E. coli and yeast systems, respectively.
3.5. Comparisons of Scaling Factors. Scaling factors of dif-
ferent enzymes based on CYP expression systems were
calculated and shown in Table 3. These scaling factor ranged
from −1.735 to 3.794. In the baculovirus expression system,
the values of scaling factors varied a lot across the enzymes
(Figure 4). And 71.4% (5/7) of the values, whose range was
−1.735 to 2.394, were positive.
The variability in the same enzyme between CYP expres-
sion systems was also different. In CYP2D6, yeast system
and lymphoblastoid system had higher variability than bac-
ulovirus systemwith the coefficient of variation (CV) 65.13%,
87.95%, and 25.10%, respectively. In CYP3A, lymphoblas-
toid system (CV = 356.60%) had higher variability than
baculovirus system (CV = 200.98%) similarly. However, in
CYP2C9 the coefficient of variation in lymphoblastoid (CV
= 153.66%) was smaller than baculovirus system (CV =
368.53%).
4. Discussion and Conclusion
In this paper, we compare the performance of different
recombinant human enzyme expression systems (including
Escherichia coli system, yeast system, lymphoblastoid system,
and baculovirus system) for predicting hepatic clearance in
human body. And we attempt to find out the most suitable
one for the large scale drug clearance prediction. After
collecting the in vitro pharmacokinetic parameters of thirty-
five probe drugs, we use in vitro-in vivo extrapolation to
predict the clearance.The experimental results (Table 2) show
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Figure 1: Predicted versus observed clearances of 28 drugs of baculovirus expression system.
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that half (24/48) of the predicted values in different in vitro
systems are within 3-fold the observed in vivo clearance
values.
The comparisons of clearance predictions for different
enzyme probe drugs from the same expression system and in
different expression systems, data availability from different
expression systems, and scaling factors are further analyzed.
Figure 2 shows that baculovirus system has almost equal
accuracy as the other systems in predicting clearance. Mean-
while, it can provide more and sufficient data for prediction
than the others (Figure 3). We should note that the scaling
factor will be enzyme dependent as shown in Table 3 and
0
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3
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−1.5
−1
−0.5
Figure 4: Comparisons of scaling factors in the baculovirus system.
in most cases baculovirus systems have the smaller CV in
scaling factors.Therefore, we shall use data of the baculovirus
system for the large scale drug clearance prediction.
Nevertheless, there are a few more caveats. Most impor-
tant of all is that in vivo clearance of some probe drugs
we collected contains the renal clearance. Some of the in
vivo clearance is obtained as the systemic clearance. And the
proportion of hepatic metabolism was not clear. Hence, the
scaling factor estimation may have some bias.
In most closely related studies, the combination of HLM
and recombinant enzymes is implemented to predict in vivo
clearance for high accuracy of in vitro-in vivo extrapolation
[52–54]. But most of them only focused on one drug, and the
choice of in vitro systems was not taken into consideration.
We are fully aware that some drugs are metabolized
through non-CYP pathways, such as oxidases, reductases,
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and other phase II metabolism enzymes. Our preliminary
research on these enzymes revealed very limited in vitro
experiment data on only a handful of drugs. Therefore, these
data cannot be scaled up to do large scale in vitro-in vivo
prediction and to evaluate their variations.
To our knowledge, this is the first study to compare
the performance of different in vitro systems and make a
decision.With the assistance of our work, the large scale drug
clearance prediction should be more effective and efficient.
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